Roman Iospa, CEO, Medical/Ophth/AI Investor

Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors Tel Aviv, Israel & Miami, Florida, Aug. 21, 2025 (Global Newswire) – BioBeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors. Biobeat developed and has received FDA clearance for an easy-to-apply “patch” device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. “We welcome Raymond W. Cohen as our new Chairman,” said Arik Ben Ishay, co-founder and CEO of Biobeat. “Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology.” “Biobeat has accomplished what has been an elusive goal for many – a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital,” said Mr. Cohen. “I look forward to collaborating with the management team to support the company’s mission to change the way patients are monitored.” Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. Cohen currently serves on the boards of several innovative healthcare companies, including Kestra (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners. About BioBeat Technologies, Ltd BioBeat based in Israel and Boca Raton, FL is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, BioBeat offers a cuff-less small unobtrusive “patch” device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat’s products are 510(k) cleared by the US Food & Drug Administration.

196

21 Comments

Israel’s medtech sector has been transforming global  healthcare for decades, here are 5 reasons why it’s a great time to invest: 1. With recent challenges, many companies have adjusted valuations, making it an ideal time to invest in promising medtech startups at attractive terms. 2. Israel’s medtech ecosystem thrives under pressure, finding creative solutions and workarounds that fuel a new wave of innovation and company growth. 3. Despite complex challenges, Israeli companies have shown their ability to stay operational, deliver results, and meet global healthcare demands. 4. Aging populations and rising healthcare costs demand scalable, impactful solutions, and Israeli MedTech is leading the way. 5. From Medtronic's Mazor Robotics to INSIGHTEC, Israel’s medtech ecosystem has a proven ability to scale globally and create impact. At TENGABLE, we’re helping restore the sense of tactile touch for millions who have lost it due to injury, chronic illness, or disease. Our innovative triboelectric nanogenerator (TENG) technology offers a revolutionary solution for tactile sensation restoration, bringing hope and innovation where it’s needed most. If you’re interested in learning more about our story feel free to reach out––my door is always open. In the below photo is Dr. Amir Amari , Tenable’s Co-Founder & CMO, and Chair of the Hand Surgery Department at Sheba Research Authority (Tel-HaShomer)

62

2 Comments

💡 𝗕𝗶𝗴 𝘀𝘁𝗲𝗽 𝘁𝗼𝘄𝗮𝗿𝗱 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗜 ? A new bipartisan bill (S.1399, the Health Tech Investment Act) would create a dedicated Medicare pathway for FDA‑cleared AI devices: - Automatic Category III NTAPC codes valid for 5 years - Payments based on the manufacturer’s cost estimate - Smoother transition to permanent CPT codes Backed by GE HealthCare, Siemens Healthineers, the proposal could finally solve the “great technology, no reimbursement” dilemma that slows AI adoption. Still early days, but encouraging to see Congress address the business model behind clinical AI. Full story via Brian Casey / The Imaging Wire Wire 👉 https://lnkd.in/eRrdMeT3 #MedicalAI #AI #Radiology #HealthPolicy

48

3 Comments

Caresyntax is honored to have three abstracts accepted at the upcoming 2025 Society of Robotic Surgery | SRS Annual Meeting. We're exploring the application of robotic approaches in comparison with other traditional approaches, and using real-world data and clinical quality improvement to evaluate true value and utility for these technologies.   Our Accepted Abstracts:  • When is a Robotic Approach Valuable in Ventral Hernia Repair?   • Use of Robotic and Open Approaches for Ventral Hernia Repair: When is the Robot Utilized in a Busy Hernia Center?   • Deploying a Real-World Data Methodology for Robotics Innovation: A Meta-Analysis of Robotic, Laparoscopic, and Open Techniques Across Multiple Projects This work wouldn’t be possible without the collaboration of our clinician partners and fellow data scientists. Our mission: to move from clinical anecdote to actionable insight in surgical innovation.

56

1 Comment

MedTech Industry Update - Week 39, 2025 #RegApprovals Techsomed got FDA 510k to expand its platform for percutaneous ablation of soft tissue in the kidney Yossi Abu Brainlab won 510k for its Spine Mixed Reality Navigation Sean Clark Neuromod secured MDR certification for Lenire its neuromodulation device to treat tinnitus Ross O'Neill Virtuoso Surgical, Inc. received Breakthrough Device Designation for en bloc excision of bladder lesions with its robotic system. Trials in urology are ongoing Duke Herrell Heartflow won FDA 510k for its next-gen Plaque Analysis algorithm, improving plaque detection by 21% John Farquhar Biolinq received FDA de novo classification for its Shine wearable sensor, which could become the first needle-free CGM in the US Rich Yang EndoRobotics Co., Ltd. got FDA 510k for its endoscopic robotics system under multiple product codes Bunkerhill Health announced FDA clearance for ECG-EF, enabling reduced ejection fraction screening from routine 12-lead ECGs CIONIC received FDA clearance for its nextgen Neural Sleeve #Funding / M&A Sencilia raised funding from Future Tech Ventures and imec.istart to advance its infusion sensor Amar Kamat Leo Cancer Care closed a $40M round led by Catalio Capital to expand commercialisation of the Marie upright radiotherapy system Stephen Towe Axon Therapies Inc. raised $32M Series A co-led by Earlybird and Santé to advance the Satera Ablation System for heart failure Navigation Sciences received a $400K STTR Phase 1 grant from the NCI to advance the NaviSci System for precision lung cancer surgery Alan Lucas Micro-X secured a $4.4M grant from the Australian Government to launch a world-first stroke imaging trial using a compact Head CT scanner in standard ambulances VESTECK, Inc was awarded a $1.9M NIH grant to advance its “Suture-Tight” catheter for endograft fixation in abdominal aortic aneurysm repair Joseph W. Rafferty Glooko acquired Monarch Medical Technologies expanding its diabetes platform into inpatient glucose management Mike Alvarez Toothfairy ™ raised £7.3M for its digital dental platform #Innovation & Updates Dornier MedTech launched 2 single-use devices in the US: Hoover Flexible Suction Access Sheath and Axis II Slim ureteroscope Brock Faulkner Insight Medbotics unveiled Glenn an MRI-compatible surgical robot for #prostatecancer Fazila Seker Morphic Medical announced the first commercial use of Reset its incision-free therapy for obesity and type2 diabetes Mike G. Laza Medical achieved FIH use of its AI-driven heart model for ultrasound-guided cardiac procedures Stereotaxis’ Genesis robotic system performed its first procedures in NL Medtronic advanced trials with its novel urinary incontinence device and treated the first patient with the AltaViva #neuromod system Xeltis reported positive data for its #vascular access device RenovoRx (Nasdaq: RNXT) treated the first patient with RenovoCath 📩 If you're building in #MedTech we’re watching. DM us to share your update

162

6 Comments

6:8 Medical Solutions and Sago Medica Announce Strategic Partnership to Distribute Life-Saving Hemorrhage Control Devices Across Italy Myrtle Beach, SC – 6:8 Medical Solutions, a veteran-owned small business specializing in innovative emergency medical technologies, is proud to announce a strategic partnership with Sago Medica, a leading distributor of advanced medical devices throughout Italy. This collaboration will bring the Popp Point Pressure™ family of hemorrhage control devices and products to emergency responders, hospitals, and military medical providers across the Italian healthcare system. Founded and led by Uriah Popp, a former U.S. Army Special Operations Medic, 6:8 Medical Solutions developed the Popp Point Pressure™ family of products to address the urgent need for rapid, effective control of compressible hemorrhage in both civilian and military environments. “This partnership with Sago Medica is an important step in our mission to place life-saving technology in the hands of those who need it most,” said Uriah Popp, CEO and inventor of the devices. “As a veteran and medic, I’ve seen firsthand how critical every second is when dealing with hemorrhage. Responding to trauma and providing life saving care can be stressful. Solutions must be rapidly available, intuitive to use, and simplify tasks. We design products and devices with these things in mind. It is imperative to change the outcome in those moments, .” The Popp Point Pressure™ family of products delivers focused pressure to bleeding sites, offering a novel approach to hemorrhage control in prehospital, austere, and battlefield conditions. Through this agreement, Sago Medica will distribute the full product line throughout Italy, supporting improved outcomes in trauma care. “We are honored to partner with 6:8 Medical Solutions and to introduce this revolutionary technology to the Italian market,” said Franco Fallavena, Managing Director of Sago Medica. “Uriah’s combat experience and insight have produced products that fills a vital gap in hemorrhage management as well as tourniquet conversion.” Headquartered in Myrtle Beach, South Carolina, 6:8 Medical Solutions continues to lead the way in veteran-led innovation for trauma care. For more information about the Popp Point Pressure™ Devices and distribution inquiries, visit www.68medical.com.

46

3 Comments

Global Eyewear Market Set to Reach $323.76B by 2030... A recent report by The Research Insights (https://lnkd.in/decMP6j2) reveals that the global eyewear market is poised for significant expansion, growing from $200.46B in 2024 to $323.76B by 2030, at a CAGR of 8.3%.   >> What’s driving this growth? - The global rise in vision disorders (myopia, hyperopia, presbyopia) - Increased digital screen time and demand for blue-light blocking lenses - Eyewear’s transformation into a fashion statement, especially among Gen Z and Millennials - Premium & luxury brands leveraging customization, sustainability, and limited editions - Rapid innovation in AR try-on, lightweight materials, and direct-to-consumer models   >> Asia-Pacific stands out as a high-growth region, with >7% annual growth expected, fueled by rising disposable income and increasing appetite for premium and tech-enhanced eyewear.   >> The convergence of healthcare, fashion, and technology is reshaping the optical industry. Exciting times ahead for companies that can combine vision correction with style, convenience, and personalization.   What trends are you seeing in your region or segment?

25

🔬 Innovations in Hypertriglyceridemia Treatment: A State-of-the-Art Review 📊 Hypertriglyceridemia (HTG) continues to be a challenge in managing residual cardiovascular risks and acute pancreatitis. Recent research shines a spotlight on both traditional therapies and groundbreaking advancements. ✅ Standard Therapies: While statins, fibrates, omega-3 fatty acids, and niacin remain foundational, they often fall short in cases of severe hypertriglyceridemia (sHTG) or familial chylomicronemia syndrome (FCS). 🌟 Emerging Innovations: ApoC-III Inhibitors: New-generation therapies like Olezarsen and Plozasiran have demonstrated substantial triglyceride (TG) reductions with fewer side effects compared to earlier treatments like Volanesorsen. ANGPTL3 Inhibitors: Zodasiran and others promise not only TG reduction but also improvements in lipid profiles, though challenges like hepatotoxicity with earlier candidates such as Vupanorsen underscore the need for safety refinement. FGF21 Analogues: Pegozafermin has shown potential in reducing TGs and addressing metabolic complications, with exciting phase 3 trials underway. 📌 Future Directions: Despite the progress, challenges remain in ensuring these therapies improve cardiovascular outcomes and minimize side effects. Multidisciplinary research is pivotal to translate these advances into meaningful clinical benefits. 🔗 Read the full review here: https://lnkd.in/dRADuM4S #Hypertriglyceridemia #CardiovascularHealth #MedicalInnovation #RNAtherapies #FGF21

73

12 Comments

𝗧𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗩𝗲𝗿𝘀𝗮𝘁𝗶𝗹𝗶𝘁𝘆: 𝗠𝘂𝗹𝘁𝗶-𝗜𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗔𝗲𝘀𝘁𝗵𝗲𝘁𝗶𝗰 𝗖𝗮𝗿𝗲 The landscape of aesthetic medicine is evolving, and one thing is clear—efficiency and effectiveness matter more than ever. Patients today are not just looking for single treatments; they want holistic, results-driven solutions that fit into their busy lives. That’s where the power of multi-indication treatments comes in. Modern aesthetic technology now allows clinics to combine multiple procedures in a single session, maximizing results while minimizing downtime. This trend aligns with the latest insights from leading industry research and reports, highlighting the growing demand for combination procedures in aesthetic medicine: 🔹 Time is precious – For professionals, parents, and individuals with packed schedules, long recovery times can be a major barrier. Combining treatments helps them achieve their goals without extended disruptions to their routines. 🔹 Optimized care – By offering multi-indication solutions, practitioners can customize treatments more precisely, enhancing patient outcomes and satisfaction. 🔹 Surgeon insights – According to the latest research data, 80% of surgeons report that patients actively seek combination procedures for longer-lasting results and shorter recovery times. Versatility in aesthetics is no longer a luxury—it’s the key to elevating patient care and optimizing clinic performance. The future belongs to those who can offer more, deliver faster, and maintain excellence without compromise.

40

Don't exclusively chase the golden VC ticket. Pull every lever available. Multiple funding sources = medtech magic. Here's 4 ways to put this into practice: → Layered funding strategy - grants, private investors, and strategic partners → Combine licensed IP with your own developments → Deals like asset sales can be better than chasing traditional acquisitions → Consider investment bankers early on big rounds to accelerate process Success comes from orchestrating multiple moving pieces and hedging risk. The VC market is broken and deteriorating, over rely on it at your own peril. Brian More walks through Nanovis winning strategy in the full episode on the XO Medtech YouTube Channel. We build tools that create and accelerate medtech innovators. Join XO Medtech today. #medtech #medicaldevices #startupfunding #healthtech #innovation #medtechstartup #ortho #spine #nanotechnology

27

1 Comment